Overview

Progesterone in Patients With Placenta Previa

Status:
Unknown status

Trial end date:
2019-08-01

Target enrollment:
0

Participant gender:
Female

Summary

This study evaluates the efficacy of prophylactic vaginal progesterone administration in reducing of the episodes of antepartum hemorrhage and subsequent prevention of preterm delivery in women with placenta previa.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Ain Shams University

Treatments:

Progesterone

Criteria

Inclusion Criteria:

1. Gestational age 26-28 weeks of gestation.

2. Definite and reliable diagnosis of placenta previa (defined as presence of a placenta
within 2 cm of the internal os), using a transvaginal ultrasound scan.

Exclusion Criteria:

1. Multiple pregnancy.

2. Women at high risk of preterm labor e.g. history of spontaneous preterm labor or
preterm prelabor rupture of the membranes (PPROM).

3. Severe antepartum hemorrhage and/or hemodynamic instability that necessitates urgent
intervention and delivery.

4. Women who have been maintained on progestin therapy since early pregnancy for whatever
reason.